Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674661 · ClinicalTrials.gov registry record · Phase 3
Corneal Collagen Cross-Linking for Ectasia (CXL)
A Phase 3 study of Ectasia, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT00674661 is a Phase 3 study of Ectasia that has completed, run by Glaukos Corporation. The registered enrollment target is 130 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT00674661, a Phase 3 study of Ectasia, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
Conditions Studied
Interventions
- DRUG riboflavin ophthalmic solution
- DEVICE UVA Irradiation
Study Locations (10)
California
- Shiley Eye Center - La Jolla
- Gordon -Weiss Vision Institute - San Diego
New York
- Edward Harkness Eye Institute at Columbia University Medical Center - New York
- Ophthalmic Consultants of Long Island - Rockville Centre
Florida
- Center for Excellence in Eye Care - Miami
Indiana
- Price Vision Group - Indianapolis
Kansas
- Durrie Vision - Kansas City
Maryland
- Wilmer Eye Institute at Johns Hopkins University - Baltimore
Minnesota
- Minnesota Eye Consultants - Minneapolis
New Jersey
- Cornea & Laser Eye Institute; Hersh Vision Group - Teaneck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674661
The ClinicalTrials.gov registry entry for NCT00674661 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ectasia appearing as the primary indexed condition, and to 2 interventions - of which riboflavin ophthalmic solution is the first listed.
NCT00674661 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT00674661 about?
NCT00674661 is a clinical study titled "Corneal Collagen Cross-Linking for Ectasia (CXL)". Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
What is the current status of trial NCT00674661?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2007-12. Estimated completion is 2011-11.
What conditions does trial NCT00674661 study?
This clinical trial studies the following conditions: Ectasia.
What interventions are being tested in trial NCT00674661?
The interventions under investigation include: riboflavin ophthalmic solution (DRUG), UVA Irradiation (DEVICE).
Who is sponsoring clinical trial NCT00674661?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674661 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.